Open AccessEvaluation of Early Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine Together With Nab-paclitaxel
Author(s) -
Wataru Izumo,
Ryota Higuchi,
Toru Furukawa,
Takehisa Yazawa,
Shuichiro Uemura,
Yutaro Matsunaga,
Masahiro Shiihara,
Masakazu Yamamoto
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10053
Subject(s) - gemcitabine , medicine , pancreatic ductal adenocarcinoma , hazard ratio , oncology , adenocarcinoma , multivariate analysis , paclitaxel , pancreatic cancer , chemotherapy , cancer , confidence interval
Gemcitabine together with nab-paclitaxel (GnP) has been shown to improve outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). However, the predictive markers for treatment effects remain unclear. This study aimed to identify early prognostic factors in patients with PDAC receiving GnP.